Bayer’s Collaboration and Joint Venture with Arvinas

Orrick has advised Bayer on its collaboration with biopharmaceutical company Arvinas (Nasdaq: ARVN) to leverage Arvinas’ PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological and gynecological diseases.

In addition, Bayer and Arvinas will jointly launch a new company to leverage Arvinas’ PROTAC® technology for agricultural applications. The overall series of arrangements includes over $110 million in upfront cash and committed funding for the human disease collaboration, the agricultural joint venture and a direct equity investment by Bayer in Arvinas.

Orrick advised Bayer with a team including Matthew Gemello (Picture), Ramy Shweiky, Thomas Joraanstad, Stephen Chao, Diana Gillis, Patrick Herman, Alex Okuliar and Eric Wall.

Involved fees earner: Alex Okuliar – Orrick; Stephen Chao – Orrick; Matthew Gemello – Orrick; Diana Gillis – Orrick; Patrick Herman – Orrick; Ramy Shweiky – Orrick; Eric Wall – Orrick;

Law Firms: Orrick;

Clients: Bayer;

Author: Ambrogio Visconti